Propanc Biopharma Common Stock Performance
| PPCB Stock | USD 0.51 0.03 5.56% |
The company holds a Beta of 1.48, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Propanc Biopharma, will likely underperform. At this point, Propanc Biopharma Common has a negative expected return of -1.97%. Please make sure to check Propanc Biopharma,'s potential upside and the relationship between the accumulation distribution and period momentum indicator , to decide if Propanc Biopharma Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Propanc Biopharma Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Propanc |
Propanc Biopharma, Relative Risk vs. Return Landscape
If you would invest 188.00 in Propanc Biopharma Common on October 9, 2025 and sell it today you would lose (137.00) from holding Propanc Biopharma Common or give up 72.87% of portfolio value over 90 days. Propanc Biopharma Common is currently does not generate positive expected returns and assumes 5.438% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of pink sheets are less volatile than Propanc, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Propanc Biopharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Propanc Biopharma,'s investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Propanc Biopharma Common, and traders can use it to determine the average amount a Propanc Biopharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3618
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PPCB |
Based on monthly moving average Propanc Biopharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Propanc Biopharma, by adding Propanc Biopharma, to a well-diversified portfolio.
Propanc Biopharma, Fundamentals Growth
Propanc Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Propanc Biopharma,, and Propanc Biopharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Propanc Pink Sheet performance.
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 81.65 K | |||
About Propanc Biopharma, Performance
By analyzing Propanc Biopharma,'s fundamental ratios, stakeholders can gain valuable insights into Propanc Biopharma,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Propanc Biopharma, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Propanc Biopharma, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Propanc Biopharma Common performance evaluation
Checking the ongoing alerts about Propanc Biopharma, for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Propanc Biopharma Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Propanc Biopharma, generated a negative expected return over the last 90 days | |
| Propanc Biopharma, has high historical volatility and very poor performance | |
| Propanc Biopharma, has some characteristics of a very speculative penny stock | |
| Propanc Biopharma, has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma Common currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
- Analyzing Propanc Biopharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Propanc Biopharma,'s stock is overvalued or undervalued compared to its peers.
- Examining Propanc Biopharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Propanc Biopharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Propanc Biopharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Propanc Biopharma,'s pink sheet. These opinions can provide insight into Propanc Biopharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Propanc Pink Sheet analysis
When running Propanc Biopharma,'s price analysis, check to measure Propanc Biopharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma, is operating at the current time. Most of Propanc Biopharma,'s value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma,'s price. Additionally, you may evaluate how the addition of Propanc Biopharma, to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |